KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%

被引：74

作者：

Brahmer, J. R. ^{[1
]}

Rodriguez-Abreu, D. ^{[2
]}

Robinson, A. G. ^{[3
,4
]}

Hui, R. ^{[3
,4
]}

Csoszi, T. ^{[5
]}

Fulop, A. ^{[6
]}

Gottfried, M. ^{[7
]}

Peled, N. ^{[8
]}

Tafreshi, A. ^{[9
,10
]}

Cuffe, S. ^{[11
,12
]}

O'Brien, M. ^{[13
]}

Rao, S. ^{[14
]}

Hotta, K. ^{[15
]}

Leal, T. A. ^{[16
]}

Riess, J. W. ^{[17
]}

Jensen, E. ^{[18
]}

Zhao, B. ^{[18
]}

Pietanza, M. C. ^{[18
]}

Reck, M. ^{[19
]}

机构：

[1] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Oncol, Baltimore, MD USA

[2] Hosp Univ Insular Gran Canaria, Med Oncol, Las Palmas Gran Canaria, Spain

[3] Westmead Hosp, Med Oncol, Sydney, NSW, Australia

[4] Univ Sydney, Sydney, NSW, Australia

[5] Jasz Nagykun Szolnok Cty Hosp, Oncol, Szolnok, Hungary

[6] Orszagos Koranyi Pulmonol Intezet, Med Oncol, Budapest, Hungary

[7] Meir Med Ctr, Med Oncol, Kefar Sava, Israel

[8] Soroka Univ Med Ctr, Ctr Canc, Beer Sheva, Israel

[9] Wollongong Private Hosp, Med Oncol, Wollongong, NSW, Australia

[10] Univ Wollongong, Wollongong, NSW, Australia

[11] St James Hosp, Med Oncol, Dublin, Ireland

[12] Canc Trials Ireland, Dublin, Ireland

[13] Royal Marsden Hosp, Med Oncol, Sutton, Surrey, England

[14] MedStar Franklin Sq Hosp, Med Oncol, Baltimore, MD USA

[15] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan

[16] Univ Wisconsin, Carbone Canc Ctr, Div Hematol & Oncol, Madison, WI USA

[17] UC Davis Comprehens Canc Ctr, Div Hematol Oncol, Sacramento, CA USA

[18] Merck & Co Inc, Oncol, Kenilworth, NJ USA

[19] German Ctr Lung Res, Airway Res Ctr North, Lungen Clin, Grosshansdorf, Germany

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.2284

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA51

引用

页码：S1181 / S1182

页数：2

共 50 条

[21] KEYNOTE-042: 5-year update of first-line pembrolizumab in Asian patients with locally advanced/metastatic PD-L1-positive NSCLC
Kubota, Kaoru
Cho, Byoung Chul
Srimuninnimit, Vichien
Fan, Yu
Zhou, Jianying
Zhang, Li
Zhou, Qing
Hosomi, Yukio
Takeoka, Hiroaki
Mukherjee, Rinee
Fu, Wei
Souza, Fabricio
Mok, Tony S. K.
Zhang, Li
ANNALS OF ONCOLOGY, 2022, 33 : S472 - S472
[22] Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1-positive (TPS ≥50%), advanced NSCLC in Japan
Goto, Y.
Santorelli, M. L.
Taniguchi, K.
Kamitani, T.
Irisawa, M.
Kanda, K.
Abe, M.
Burke, T.
Nokihara, H.
ANNALS OF ONCOLOGY, 2021, 32 : S1008 - S1009
[23] Real-world multicentre cohort of 1L pembrolizumab alone or in combination with platinum-based chemotherapy in NSCLC PD-L1 ≥ 50%
Pons-Tostivint, E.
Hulo, P.
Guardiolle, V.
Bodot, L.
Rabeau, A.
Porte, M.
Hiret, S.
Demontrond, P.
Curcio, H.
Boudoussier, A.
Veillon, R.
Mayenga, M.
Dumenil, C.
Gourraud, P-A.
Mazieres, J.
Bennouna, J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1060 - S1060
[24] Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.
Morales-Barrera, Rafael
Powles, Thomas
Ozguroglu, Mustafa
Csoszi, Tibor
Loriot, Yohann
Flechon, Aude
Matsubara, Nobuaki
Rodriguez-Vida, Alejo
Geczi, Lajos
Cheng, Susanna Y.
Fradet, Yves
Oudard, Stephane
Gunduz, Seyda
Ma, Junshui
Rajasagi, Mohini
Vajdi, Amir
Cristescu, Razvan
Imai, Kentaro
Moreno, Blanca Homet
Alva, Ajjai Shivaram
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[25] Pembrolizumab vs chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC) and PD-L1 TPS ≥1%: 5-year update from KEYNOTE-042
Wu, Y-L.
Zhang, L.
Fan, Y.
Zhou, J.
Zhang, L.
Zhou, Q.
Li, W.
Hu, C.
Chen, G.
Zhang, X.
Zhou, C.
Arenas, C. G.
Chen, Z.
Yu, W. C.
Mok, T. S. K.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S65 - S66
[26] Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.
Brahmer, Julie R.
Rodriguez-Abreu, Delvys
Robinson, Andrew George
Hui, Rina
Csoszi, Tibor
Fulop, Andrea
Gottfried, Maya
Peled, Nir
Tafreshi, Ali
Cuffe, Sinead
O'Brien, Mary
Rao, Suman
Hotta, Katsuyuki
Leiby, Melanie A.
McLean, Jessica
Shentu, Yue
Rangwala, Reshma A.
Reck, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[27] KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo (pbo) plus pem and platinum for metastatic nonsquamous NSCLC
Garassino, M. C.
Gadgeel, S. M.
Speranza, G.
Felip, E.
Gonzalez, E. Esteban
Gomez, M. Domine
Hochmair, M. J.
Powell, S. F.
Bischoff, H.
Peled, N.
Grossi, F.
Jennens, R.
Reck, M.
Hui, R.
Garon, E. B.
Kurata, T.
Gray, J. E.
Schwarzenberger, P. O.
Jensen, E.
Abreu, D. Rodriguez
ANNALS OF ONCOLOGY, 2022, 33 (07) : S992 - S993
[28] dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%
Holtzman, Liran
Moskovitz, Mor
Urban, Damien
Nechushtan, Hovav
Keren, Shoshana
Reinhorn, Daniel
Wollner, Mira
Daher, Sameh
Rottenberg, Yakir
Rovitzky, Yulia
Shochat, Tzippy
Bar, Jair
Dudnik, Elizabeth
CLINICAL LUNG CANCER, 2022, 23 (02) : 122 - 134
[29] A phase 3 study of first-line durvalumab vs platinum-based chemotherapy in patients with advanced NSCLC and high PD-L1 expression: PEARL
Wu, Y-L.
Lu, S.
Clarke, S.
Lactionov, K.
Li, P.
Kirkby, M.
Xie, Y.
Stockman, P.
ANNALS OF ONCOLOGY, 2017, 28
[30] A Matching-Adjusted Indirect Comparison of Pembrolizumab plus Chemotherapy vs. Nivolumab plus Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC
Halmos, Balazs
Burke, Thomas
Kalyvas, Chrysostomos
Insinga, Ralph
Vandormael, Kristel
Frederickson, Andrew
Piperdi, Bilal
CANCERS, 2020, 12 (12) : 1 - 15

← 1 2 3 4 5 →